An open label clinical trial of thalidomide in NSAIDs refractory ankylosing spondylitis

References

• Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346–52.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000;59:428–33.
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699–703.
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–80.
   PubMed Web of Science ®Google Scholar
• Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol. 1997;159:5157–61.
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.
   PubMed Web of Science ®Google Scholar
• Appel H, Meir R, Bleil J, Hempfing A, Loddenkemper C, Schlichting U, et al. In situ analysis of interleukin-23 and interleukin-12 positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 2013;65(6):1522–9.
   PubMed Web of Science ®Google Scholar
• Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol. 1998;25:964–9.
   PubMed Web of Science ®Google Scholar
• Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatology. 2003;121(5):1060–5.
   PubMed Web of Science ®Google Scholar
• Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol. 1996;81:219–23.
   PubMedGoogle Scholar
• Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168:408–14.
   PubMed Web of Science ®Google Scholar
• Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.
   PubMed Web of Science ®Google Scholar
• Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H, Kennedy LG, OHea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
   PubMed Web of Science ®Google Scholar
• Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21:1694–8.
   PubMed Web of Science ®Google Scholar
• Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DT. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum. 2002;47:249–54.
   PubMed Web of Science ®Google Scholar
• Lenardo TM, Calabrese LH. The role of thalidomide in the treatment of rheumatic disease. J Clin Rheumatol. 2000;6:19.
   PubMed Web of Science ®Google Scholar
• Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondylarthropathies. Rheum Dis Clin North Am. 1995;21:117–28.
   PubMed Web of Science ®Google Scholar
• Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. 1999;42:580–1.
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006;33:722.
   PubMed Web of Science ®Google Scholar
• Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Extended report; Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002;61(Suppl III):iii40–50.
   Web of Science ®Google Scholar
• Keesal N, Wasserman MJ, Bookman A, Lapp V, Weber DA, Keystone EC. Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol. 1999;26:2344–7.
   PubMed Web of Science ®Google Scholar
• Wei JC, Chan TW, Lin HS, Huang F, Chou CT. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol. 2003; Dec30(12):2627–31.
   PubMed Web of Science ®Google Scholar
• Mellin GW, Katzenstein M. The saga of thalidomide (concluded): neuropathy to embryopathy, with case reports of congenital abnormalities. N Engl J Med. 1962;267:1238–44.
   PubMed Web of Science ®Google Scholar